TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00772928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Description: 0.5 mL, Intramuscular
Study: NCT03730298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng
Description: cpr

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cpr
Study: NCT01192087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
Study: NCT02734368

Intervention type: DRUG
Intervention: Hyperpolarized Helium-3

Intervention type: DRUG
Intervention: Hyperpolarized Helium-3

Intervention type: DRUG
Intervention: Hyperpolarized Helium-3
Study: NCT02264392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Incision and Drainage
Description: Ultrasound guidance of the abscess drainage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind Incision and Drainage
Description: Incision and drainage of abscess guided by physical exam alone
Study: NCT01019356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4 mg twice daily for 8 weeks orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: 100 mg three times daily for 8 weeks orally
Study: NCT03233165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute.
Study: NCT04190446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT02510274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325
Description: oral
Study: NCT03266653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytotoxic t-lymphocytes
Description: EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
Study: NCT03233165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Description: Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
Study: NCT00811187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine paracervical block
Description: 5cc 1% lidocaine injection in each paracervical region

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 5cc Normal Saline injection in each paracervical region
Study: NCT05391204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Tests
Description: Various physical exercices of inferior members

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Tests
Description: Various physical exercices of inferior members
Study: NCT03791177

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Music Therapy
Description: Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy
Study: NCT01127776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APOS SYSTEM
Description: The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: APOS SYSTEM without biomechanics units.
Description: The control group will receive the same walking protocol as the trial group without biomechanics units
Study: NCT03184649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: It is a pre-analgesic will be taken before painful procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: it is a pre-analgesic drug will be taken before painful procedure.
Study: NCT01134809

Intervention type: PROCEDURE
Intervention: Major abdominal surgery
Description: All adult patients having major abdominal surgery
Study: NCT03766828

Intervention type: PROCEDURE
Intervention: inside-out-access technique with inside-out access device (Surfacer (R))
Description: inside-out-access technique with (Surfacer (R)) with a new CE certified device (Surfacer (R), Bluegrass Vascular)

Intervention type: PROCEDURE
Intervention: access technique including Sharp recanalization
Description: access technique with Sharp recanalization via interventional radiology
Study: NCT01607970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
Study: NCT01697787

Intervention type: DRUG
Group type: OTHER
Intervention: Amodiaquine-Artesunate
Description: If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.

Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine
Description: If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
Study: NCT00184028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
Study: NCT03232190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Application
Description: Parents receive a web application that offers information and support until the age of 2.
Study: NCT04317170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia during their routine standard of care dermatologic procedure
Study: NCT00812630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MENT or placebo
Description: A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
Study: NCT01447797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0912 / Irbesartan and Atorvastatin
Description: Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP0912 / Irbesartan and Atorvastatin
Description: Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
Study: NCT04612309

Intervention type: DRUG
Intervention: Immunotherapy
Description: patient treated with at least 1 immunotherapy administration
Study: NCT01167023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally, once daily for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally, once daily for 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily for 30 days.
Study: NCT02747264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eRAPID
Description: eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
Study: NCT01253200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blazer® Open-Irrigated Ablation Catheter
Description: Blazer® Open-Irrigated Ablation Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Catheter
Description: Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
Study: NCT00910884

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: No supplements are given

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: No supplements are given

Intervention type: PROCEDURE
Intervention: therapeutic dietary intervention
Description: Given orally daily for 12 months
Study: NCT01506921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic ketamine
Description: 0.6 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine
Description: 0.3 mg/kg
Study: NCT03423901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
Study: NCT02605499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV-C light disinfection
Description: UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
Study: NCT01700530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statins (40mg/day)for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise only
Description: 12 weeks of exercise training (5 days a week for 45-50 min a session)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Statins + Exercise
Description: Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
Study: NCT01630083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
Study: NCT02253238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Survey
Description: Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
Study: NCT02253238

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of Life Survey
Description: Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Management Surveys
Description: Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
Study: NCT04376268

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash with boric acid (2.5%)
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Boric acid mouthwash (2%)
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
Study: NCT02391623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
Study: NCT02821910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted
Description: High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
Description: 1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
Description: Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
Description: 1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
Study: NCT03026088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
Study: NCT02253238

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Management Surveys
Description: Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring Devices
Description: Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
Study: NCT01630083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
Study: NCT01630083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
Study: NCT01278303

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment of Aortic Wall Injury
Description: A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
Study: NCT01020539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning Regimen
Study: NCT03184649

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: A fruit-flavored orange color placebo solution
Description: orange juice as a comparative group.
Study: NCT03492476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circaid
Description: Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~* Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-stretching Bandage (Reference treatment)
Description: Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~* DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night
Study: NCT01020539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Conditioning Regimen